Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) has been granted a patent over the use of its discovery Milciclib in combination with tyrosine kinase inhibitor (TKIs) drugs for the treatment of hepatocellular carcinoma (HCC) and other cancers.
“We are delighted that we now have this key patent on use of Milciclib in combination with other HCC drugs, including a TKI,” Dr Kunwar Shailubhai, the company’s chief executive said in a statement.
“Issuance of this patent strengthens our clinical strategy as we move forward with the combination of Milciclib and a TKI for the clinical evaluation of advanced cases of HCC as well as in patients with recurrent HCC after liver transplantation," he added.
While HCC is the most common type of primary liver cancer, multiple underlying mechanisms mean that not every case is the same.
Also, patients often develop resistance to the standard of care drug and other single treatments.
As such, combination therapies such as Milciclib with cancer growth blockers like Nexavar, Stivarga or Lenvima offer the potential for “superior outcomes”, according to Tiziana's Shailubhai.
Indeed, pairing up potentially complementary therapies has become commonplace in this era of personalised medicine.
Two posters presented to ASCO, the world’s leading cancer conference, hint to Milciclib’s potential.
The first revealed the drug, a cyclin-dependent kinases inhibitor designed to halt cancer cell division, was well-tolerated and produced “encouraging clinical activity”.
The second poster assessed Milciclib’s use alongside a TKI called Regorafenib in transplant patients where the liver cancer had returned. The combination was deemed safe while producing a “promising” response.